New drug duo aims to tackle rare leukemia

NCT ID NCT07690761

ENROLLING_BY_INVITATION Disease control Sponsor: Bnai Zion Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of two drugs, rituximab and zanubrutinib, in people with hairy cell leukemia or its variant. The goal is to see if this treatment can shrink or eliminate the cancer. Participants take zanubrutinib pills daily and receive rituximab infusions, with response checked after 32 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab and zanubrutinib
What this could lead to: If successful, this combination could offer a new, effective treatment option for people with hairy cell leukemia or its variant.
What could go wrong: This is a small, early-phase study with only 12 participants, so results may not apply broadly. The drugs can cause side effects like infections or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hairy cell leukemia hairy cell leukemia variant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAIRY CELL LEUKEMIA HAIRY CELL LEUKEMIA VARIANT

Contacts and locations

Show contact details

Locations

Bnai Zion

Haifa, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.